If I use prescribed medicinal cannabis, does that mean I have cannabis use disorder?

Not automatically. Cannabis use disorder under the DSM-5 is a cluster of criteria that includes tolerance, withdrawal, taking more than intended, difficulty cutting down, cravings, and continued use despite harm. The clinical debate is that tolerance and withdrawal are expected physiological effects of any medication used regularly — they are not by themselves signs of problematic use. Whether you have cannabis use disorder in any meaningful clinical sense depends on the full picture: whether your use is within the prescribed parameters, whether it is causing harm to your functioning or relationships, and whether you have lost control of your use. Your prescribing GP or specialist is the right person to have that conversation with.

Can a cannabis use disorder diagnosis affect my insurance or legal standing?

Potentially, yes. Clinical notes follow patients through the health system and can be accessible to insurers, medicolegal assessors, and in some circumstances employers. The concern raised by addiction medicine specialists is that a cannabis use disorder diagnosis on a patient's record — applied because of tolerance and withdrawal from a prescription — may affect how that patient is treated by other clinicians and systems, without accurately describing their clinical situation. If you have concerns about what is documented in your record, it is worth discussing directly with your prescribing doctor.

Prescribed cannabis and 'use disorder': why the label matters

What just happened

A study reported in Australian Doctor this week has surfaced a diagnostic question with practical consequences for the hundreds of thousands of Australians now prescribed medicinal cannabis: should prescribed use that produces tolerance and withdrawal be classified as cannabis use disorder?

Addiction medicine specialists say no — and they are calling for the DSM-5 criteria to be applied differently when cannabis is part of a clinical prescription.

An analysis of 2,054 anonymous patient self-reports found that 20% of medicinal cannabis users met the DSM-5 criteria for cannabis use disorder. Among the 986 participants using cannabis exactly as prescribed, the figure was 20%. When tolerance and withdrawal were excluded from the diagnostic count — on the grounds that both are expected physiological responses to regular prescribed use — the proportion fell to 9%.

The argument is not that medicinal cannabis is without risk. It is that the current diagnostic tools were not designed with prescribed use in mind.

Both-and

The inconsistency at the heart of the diagnosis

The DSM-5 criteria for substance use disorder include a cluster of items: taking more than intended, difficulty cutting down, cravings, continued use despite harm to relationships or functioning, and — the contested pair — tolerance and withdrawal. For most substances assessed in the context of non-prescribed use, tolerance and withdrawal are useful markers of significant physiological dependence.

The problem is that tolerance and withdrawal are also the expected physiological effects of using any medication regularly.

Consider how this plays out with other substance classes. A patient on long-term opioids for chronic pain is not diagnosed with opioid use disorder simply because they have developed tolerance to their dose or would experience withdrawal on sudden cessation. The same logic applies to benzodiazepines, antidepressants, and beta-blockers. Clinical practice has long recognised that prescribed-use physiological dependence and problematic-use disorder are different things that require different frameworks.

Medicinal cannabis — now widely prescribed in Australia for pain, sleep disorders, anxiety, and a range of other indications — has not yet had that distinction formally codified in diagnostic guidelines. The result is that a patient using their prescription within parameters, who has developed tolerance because that is what happens with regular cannabis use, may be meeting the threshold for a disorder they do not clinically have.

Why the label matters beyond the consulting room

It is tempting to treat this as a definitional debate that clinicians can manage informally. The concern from addiction medicine specialists is that the consequences of the wrong diagnostic label are concrete.

A cannabis use disorder entry in a patient’s clinical record affects insurance eligibility, medicolegal assessments, and the treatment pathways offered by other clinicians. It shapes how future clinicians read the history. And critically, it may discourage patients from disclosing their medicinal cannabis prescription at all — particularly in work, insurance, or legal contexts where “cannabis use disorder” carries a stigma that “prescribed medication” does not.

A 9% prevalence is meaningfully different from 20%. The 11-percentage-point gap represents real people who, under current criteria, may carry a diagnostic label that does not accurately describe their relationship with a drug they were prescribed. That has downstream effects the diagnostic system was not designed to create.

My two cents

This is a case where the diagnostic system has not kept pace with a clinical reality that has moved quickly. The call for revised criteria is clinically logical — the same principle that distinguishes opioid dependence from opioid use disorder has always existed in practice, and formalising a parallel distinction for prescribed cannabis is consistent with that tradition.

What has not yet happened is consensus. This proposal is at the advocacy and research stage, not settled in revised guidelines. The DSM-5 does not yet formally distinguish prescribed-use tolerance from disorder, and neither do most clinical protocols.

If you are using prescribed medicinal cannabis and have questions about how your use is being documented or assessed, that is worth raising directly with your prescribing GP or specialist. A careful prescriber documents the indication, the dose, and the prescribing rationale — which creates the clinical context that distinguishes prescribed-use from problematic-use if the record is reviewed later.

The addiction medicine community raising this issue is not arguing that medicinal cannabis is risk-free. It is arguing that the tools used to assess those risks need updating.

Verdict: maybe — the diagnostic revision is clinically logical and the data is suggestive, but the argument is at the advocacy stage and based on self-report data; watch for guideline bodies to respond.

Sources cited

‘Not just semantics’: Addiction experts want prescription cannabis use disorder recognised as a new condition. Australian Doctor, 26 August 2026. https://www.ausdoc.com.au/news/not-just-semantics-addiction-experts-want-prescription-cannabis-use-disorder-recognised-as-new-condition/